Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Investor Presentation (January 2008)
26 slides from Lisata Therapeutics's investor presentation, Jan 9, 2008
Slide 1: Investor Overview
NeoStem« Investor Overview Robin Smith, MD, MBA CEO and Chairman of the Board (AMEX: NBS)
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business,
Slide 3: Company Overview
Company Overview* NeoStem has a growing nationwide network of adult stem cell collection centers, enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered the research an
Slide 4: Company Highlights
Company Highlights . Multiple revenue streams through patient collection fees, processing center collection fees, and storage fees, which represent recurring revenue . Cumulative recurring revenue stream from storage fees could mean base of 5,000 patients yields approximately $2 million per year in
Slide 5: Agenda
Agenda * The Stem Cell Therapy Landscape + Platform Business + Why Should a Person Collect Today? + How Our Platform Differs From Cord Blood Industry + Our Broad Market + Recent Events * Our Business Model + The Team + Capital Structure + Investor Considerations 0°. Ne@Stem
Slide 6: Projected U.S. Stem Cell Therapy Sales
Projected U.S. Stem Cell Therapy Sales ‘segnnone seu76.06 8000000 Stem Cell Therapy: esono000 A $20 billion worldwide gs ial $6,046,551 Sane: market by 2010 ry 2 . gree --Frost & Sullivan $4.741545 “stoma 2 $322.50 sssoo0000 < $2,335,116 ss2onnone sianisis 00000 $707,332 se so. ap [8900 $180s saesss
Slide 7: 70+ Diseases Treated w/Stem Cells
70+ Diseases Treated w/Stem Cells Results for many have been quite encouraging Heart Disease “It saved my life... my own stem cells,” BERNIE ‘Adult Stem Cell Heart Recipient Lupus “My Lupus has been in remission for more than S years..” KatTHy ‘Adult Stem Cell Recipient fi Multiple Sclerosis “Stem C
Slide 8: Virtually All Therapeutic Areas
Virtually All Therapeutic Areas Over 1500 Adult Stem Cell Clinical Trials Over 500 Specific to Autologous Use + New Therapies could be on the Market in 5-10 Years — Autoimmune — Diabetes/Metabolic cea — Cardiovascular Clinical Trials.gov - Orthopedic Fracture 2 Months Post BMSC 0°. Ne@Stem 8
Slide 9: Cardiovascular Clinical Trials
402 Cardiovascular Clinical Trials One Indication Only! Institution Location H Condition Length of Study Helsinki University Finland 60 Heart Failure 2006-2009 Texas Heart Institute Houston 60 CAD 2006-2008 Rigshospitalet Copenhagen 40 Atherosclerosis 2005-2009 Minneapolis Heart Minneapolis 60 Recen
Slide 10: Platform Business
Platform Business NeoStem has a proprietary, safe and non invasive way for adults to have their stem cells collected today and stored for future use. Our platform will allow doctors and patients ready access to their cells as therapies become available in the future. Neesiem 10
Slide 11: Why Collect Today?
Why Collect Today? Finding an ostensively “matching” donor is very difficult People are dying on the “wait list” (4 mo. avg.) Rejection-Graft vs. Host Disease (40% chance even if “perfect” match) Risk of transmission of communicable disease Possible reluctance to collect and use autologous cells onc
Slide 12: Intellectual Property
Intellectual Property + 4 Patent Applications Pending on Platform Business: - Collection of adult stem cells from peripheral blood of healthy individuals for future use to treat various diseases of the individual — Process by which NeoStem prepares and stores stem cells collected from peripheral blo
Slide 13: Our Platform Differs From Cord Blood Industry
6°. Ne@Stem Our Platform Differs From Cord Blood Industry CONSIDERATION, CORD BLOOD NEOSTEM Time of Collection Birth Adulthood Addressable market 4 million births in US per annum 50+ million in U.S. with diseases where stem cell therapies are used as a currently available treatment or for which stem
Slide 14: A Broad Target Market
A Broad Target Market * People with family history of disease « Patients in a pre-disease or early-disease states + Parents who have banked their children’s cord blood + First responders — military personnel — Policemen, firemen, EMS * Industry (workers facing exposure to radiation/chemicals) By 201
Slide 15: Recent Events
Recent Events Closed on $6,350,000 in August 2007 Listed on the American Stock Exchange Launched Las Vegas collection center Signed multi-center agreement initially to expand on West Coast and Midwest with Stem Collect, LLC founded by James Doty, MD, former CEO of $1B Nasdaq Medical Device Co. Accur
Slide 16: Exclusive World Wide VSEL License
Exclusive World Wide VSEL License Very Small Embryonic-Like (VSELs) Stem Cells + Each of us has a population of very primitive embryonic like stem cells that have remained dormant in our bodies since birth - Can be mobilized in the blood using NeoStem Process — Should be easily recovered — Cryoprese
Slide 17: Our Revenue Model
Our Revenue Model + Current: Collection center fees Collection from patients Processing patient cells Storage (recurring revenue) + Potential: Utilization fees Supplier of stem cells for research Collection fees for trials Government/military contracts SBIR grants Licensing of technology 17
Slide 18: Disclaimer: Slide is for Demonstration Purposes Only
Disclaimer: Slide is for Demonstration Purposes Only EBIT SENSITIVITY Does not include annual storage $8,000,000 $6,000,000 $4,000,000 Overhead E $2,000,000 8 — $3,000,000 t — $3,500,000 t a — $4,000,000 ma PLL ILL LSE POS ‘$(2.000,000) $(4,000,000) + (6,000,000) Annual Collections Assumes direct co
Slide 19: Disclaimer: Slide is for Demonstration Purposes Only
Disclaimer: Slide is for Demonstration Purposes Only Annual Recurring Revenue Assumes Collections Abruptly Stop After 5 years (for demonstration purposes) $4,500,000 54,000,000 $3,500,000 $3,000,000 cumulative ae sollections $2,000,000 pena $2,500,000 . coe $2,000,000 eee $500,000 i & a2 28s era gy
Slide 20: Disclaimer: Slide is for Demonstration Purposes Only
E B l T 0°. Nee@stem Disclaimer: Slide is for Demonstration Purposes Only EBIT SENSITIVITY Includes annual storage $8,000,000 $6,000,000 $4,000,000 + Breakeven Point (drops by 285 collections per each 1,000 storage clients) $2,000,000 Overhead PPPS PP ee Pe — $3,000,000 — $3,500,000 — $4,900,000 $(2
Slide 21: NeoStem Management & Senior Staff
NeoStem Management & Senior Staff Robin Smith, M.D., MBA, Chief Executive Officer and Chairman of the Board. Dr. Smith has acted as a senior advisor and investor to both publicly traded and privately held companies where she has played a signfcant role restructuring andior growing the companies. Dr.
Slide 22: Scientific Advisory Board
Scientific Advisory Board Wayne A. Marasco, M.D., Ph.D. Chairman - Chairman of Scientific Advisory Board. Associate Professor- Department of Cancer and Immunology & AIDS at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. He is taking the lead in expand
Slide 23: Advisory Board
Advisory Board ; Ron Rothenberg MD, FACEP, Dr. Rothenberg is a Fellow of the American College of Emergency Physicians (FACEP) and is the founder of the California HealthSpan Institute in Encinitas, California. He was the 10th M.D. in the world to become fully board certfied by the American Board of
Slide 24: Capitalization
Capitalization At January 7, 2007 Shares Common Stock 4,879,237 Stock Options 1,141,300 Weighted average exercise price = $5.68 Warrants 2,087,938 Weighted average exercise price = $7.04 Fully Diluted Ownership 8.108.475 NBS Price Per Share: S155 Market Capitalization $7.56 million Stock Symbol (AME
Slide 25: Investment Considerations
Investment Considerations + Exponential potential earnings leverage with small number of physicians joining network (approximately 200) * 1 collection per month minimum from each physician is projected to yield approximately $20,000 per year to EBIT, 5 collections per month is projected to yield app
Slide 26: Questions
Questions Robin Smith, MD MBA NeoStem, Inc. Chairman & CEO 420 Lexington Avenue Direct: (212) 584-4174 Suite 450 Email: rsmith@neostem.com New York, NY 10170 Main: (212) 584-4180 Fax: (646) 514-7787 www.neostem.com 1.888.STEM BANK 6°. NeeStem